1. Bosch JL, Hop WC, Kirkels WJ, Schröder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 1995;46(3 Suppl A):34-40. PMID:
7544515
2. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs FD, Fourcade R, et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 2003;92:409-14. PMID:
12930430
3. Witjes WP, de la Rosette JJ, Donovan JL, Peters TJ, Abrams P, Kay HE, et al. The International Continence Society “Benign Prostatic Hyperplasia” Study: international differences in lower urinary tract symptoms and related bother. J Urol 1997;157:1295-300. PMID:
9120925
4. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253-6. PMID:
12771763
5. Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005;174(4 Pt 1):1334-8. PMID:
16145414
6. Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008;102:1133-9. PMID:
18510659
8. Yokoyama O, Homma Y, Yamaguchi O. Imidafenacin, an antimuscarinic agent, improves nocturia and reduces nocturnal urine volume. Urology 2013;82:515-20. PMID:
23876590
9. Smith AL, Wein AJ. Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant? BJU Int 2011;107:1550-4. PMID:
21518417
10. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7. PMID:
9224329
11. Chapple CR, Smith D. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol 1994;73:117-23.
12. Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O; TAABO Study Group. Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Low Urin Tract Symptoms 2011;3:29-35. PMID:
26676349
13. Takeda M, Nishizawa O, Gotoh M, Yoshida M, Takahashi S, Masumori N. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study. Urology 2013;82:887-93. PMID:
23953605
14. Gong M, Dong W, Huang G, Gong Z, Deng D, Qiu S, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin 2015;31:1781-92.
15. Vader JP. Randomised controlled trials: A User’s guide. BMJ 1998;317:1258. PMID:
9794885
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. PMID:
3802833
17. Cho S, Kwon SS, Lee KW, Yoo TK, Shin DG, Kim SW, et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. Int J Clin Pract 2017;71.
20. Yamanishi T, Asakura H, Seki N, Tokunaga S. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study). Int J Urol 2017;24:525-31. PMID:
28466585
21. Kobayashi F, Yageta Y, Yamazaki T, Wakabayashi E, Inoue M, Segawa M, et al. Pharmacological effects of imidafenacin (KRP-197/ ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 2007;57:147-54.
22. Murakami S, Yoshida M, Iwashita H, Otani M, Miyamae K, Masunaga K, et al. Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int 2003;71:290-8. PMID:
14512651
24. Kawabe K. Latest frontiers in pharmacotherapy for benign prostatic hyperplasia. Yakugaku Zasshi 2006;126 Spec no.:199-206.
25. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003;170(2 Pt 1):498-502. PMID:
12853808
26. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group Urology 1998;51:892-900. PMID:
9609623
27. Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1cadrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995;76:325-36. PMID:
7551841
28. Yamaguchi O, Kakizaki H, Homma Y, Takeda M, Nishizawa O, Gotoh M, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. Urology 2011;78:126-33. PMID:
21601248
29. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency. J Urol 2013;189(1 Suppl):S129-34. PMID:
23234618
30. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28. PMID:
17105794
31. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009;56:534-41. PMID:
19070418
32. Shi H, Chen H, Zhang Y, Cui Y. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials. Neurourol Urodyn 2020;39:1255-63. PMID:
32421908
33. Homma Y, Gotoh M, Kawauchi A, Kojima Y, Masumori N, Nagai A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 2017;24:716-29. PMID:
28748576
34. Wada N, Watanabe M, Kita M, Matsumoto S, Osanai H, Yamaguchi S, et al. Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder. Urol Int 2012;89:215-21. PMID:
22832092
35. Matsuta Y, Yusup A, Tanase K, Ishida H, Akino H, Yokoyama O. Melatonin increases bladder capacity via GABAergic system and decreases urine volume in rats. J Urol 2010;184:386-91. PMID:
20488476
36. Bunniran S, Davis C, Kristy R, Ng D, Schermer CR, Uribe C, et al. A prospective study of elderly initiating mirabegron versus antimuscarinics: patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments. Neurourol Urodyn 2018;37:177-85. PMID:
28370541
37. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor--which is the main mechanism of action? Eur Urol 2003;43:1-5. PMID:
12507537
38. Yamanishi T, Asakura H, Seki N, Tokunaga S. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study). Low Urin Tract Symptoms 2019;11:115-21. PMID:
30358116